Trial finds no benefit of adding nivolumab to tivozanib for advanced kidney cancer

In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the addition of the immune checkpoint inhibitor (ICI) nivolumab to treatment with tivozanib for patients with advanced clear cell renal cell carcinoma, a form of kidney cancer.

Novaliq pursues EMA approval for dry eye disease drug – Pharmaceutical Technology

CyclASol is an eye drop solution for dry eye disease. Credit: Andrii Borodai via Getty Images. The European Medicines Agency (EMA) accepted Novaliq’s marketing authorisation

August 24, 2023

Oscar is winding down its small employer health plans with Cigna

(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Oscar Health said Tuesday it plans to

May 8, 2024

CDC: Kids Born During the Pandemic Got Fewer Routine Vaccinations

Fewer children born during the first 2 years of the COVID-19 pandemic received recommended vaccines compared with those born in the 2 years before the

September 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.